Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label, Randomized, Multi-Center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer.

Trial Profile

A Phase 2 Open-Label, Randomized, Multi-Center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Leuprorelin; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms Neo-Abi trial
  • Sponsors Janssen Research & Development

Most Recent Events

  • 13 Feb 2021 Results of pooled analysis of post-RP outcomes from four clinical trials (NCT00298155; NCT00924469; NCT01547299; NCT02268175) presented at the 2021 Genitourinary Cancers Symposium
  • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
  • 05 May 2013 Primary endpoint 'Testosterone-levels' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top